Compare SSB & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSB | BIO |
|---|---|---|
| Founded | 1933 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.2B |
| IPO Year | 1997 | N/A |
| Metric | SSB | BIO |
|---|---|---|
| Price | $95.84 | $307.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $115.58 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 772.7K | 158.4K |
| Earning Date | 01-22-2026 | 10-29-2025 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | ★ 12.25 | N/A |
| EPS | ★ 7.27 | N/A |
| Revenue | $2,324,984,000.00 | ★ $2,557,500,000.00 |
| Revenue This Year | $57.78 | $1.77 |
| Revenue Next Year | $3.46 | $2.30 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ 39.42 | N/A |
| 52 Week Low | $77.74 | $211.43 |
| 52 Week High | $110.15 | $373.69 |
| Indicator | SSB | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 68.03 | 44.85 |
| Support Level | $90.71 | $307.08 |
| Resistance Level | $96.73 | $319.50 |
| Average True Range (ATR) | 1.88 | 8.47 |
| MACD | 0.91 | -1.43 |
| Stochastic Oscillator | 91.85 | 6.82 |
SouthState Bank Corp is a United States-based bank holding company. It provides a wide range of services and products to its customers through a wholly-owned bank subsidiary. The Bank provides retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans through financial centers in Alabama, Florida, Georgia, North Carolina, South Carolina, and Virginia. These services include demand, time and savings deposits, lending and credit card servicing, ATM processing, and wealth management and trust services.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.